Mainz Biomed (MYNZ) Stock Price, News & Analysis

Company Overview

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer. ColoAlert® has received CE marking for commercialization in Europe and is part of Mainz Biomed’s strategy to address gaps in current screening programmes by offering an alternative to traditional colonoscopy and immunochemical fecal occult blood tests.

Founded as a spin-off from the Johannes Gutenberg University Mainz, Mainz Biomed has leveraged academic research in epigenetics to build a clinical pipeline focused on gastrointestinal cancers. The firm has established partnerships with clinical research centres and diagnostic laboratories across Europe, and it is conducting studies to support regulatory submissions in the United States. Through these collaborations, Mainz Biomed aims to validate its assays in diverse patient populations and support the integration of epigenetic testing into standard screening protocols.

Led by a management team with deep experience in biotechnology, molecular diagnostics and regulatory affairs, Mainz Biomed continues to expand its product portfolio and broaden its geographic footprint. The company is pursuing additional indications beyond colorectal cancer and is investing in research and development to refine its platform for the early detection of other tumor types. As it advances clinical validation and navigates regulatory pathways, Mainz Biomed seeks to establish itself as a leader in epigenetic diagnostics and preventive oncology.

Key Stats

• Today's Range: $1.59 to $1.61
• 50-Day Range: $1.33 to $2.13
• 52-Week Range: $1.30 to $16.04
• Volume: 2,530 shs
• Average Volume: 177,704 shs
• Market Capitalization: $7.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Moderate Buy

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Mainz Biomed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Mainz Biomed has a consensus price target of $14.00, representing about 769.6% upside from its current price of $1.61.

Amount of Analyst Coverage

Mainz Biomed has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mainz Biomed are expected to grow in the coming year, from ($23.60) to ($9.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.38% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently decreased by 26.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.38% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently decreased by 26.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for MYNZ on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

3 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

MYNZ Stock Analysis - Frequently Asked Questions

How have MYNZ shares performed this year?

Mainz Biomed's stock was trading at $4.32 at the start of the year. Since then, MYNZ stock has decreased by 62.7% and is now trading at $1.61.

How were Mainz Biomed's earnings last quarter?

Mainz Biomed NV (NASDAQ:MYNZ) announced its quarterly earnings results on Tuesday, August, 15th. The company reported ($22.40) EPS for the quarter, missing the consensus estimate of ($16.80) by $5.60. The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.25 million.

When did Mainz Biomed's stock split?

Shares of Mainz Biomed reverse split on Tuesday, December 3rd 2024.The 1-40 reverse split was announced on Friday, November 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Mainz Biomed IPO?

Mainz Biomed (MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO.

Who are Mainz Biomed's major shareholders?

Mainz Biomed's top institutional investors include Armistice Capital LLC (6.23%).

How do I buy shares of Mainz Biomed?

Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mainz Biomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mainz Biomed investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), NVIDIA (NVDA), Ford Motor (F), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD) and PayPal (PYPL).

Company Calendar

• Last Earnings: 8/15/2023
• Today: 9/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MYNZ
• CIK: 1874252
• Web: mainzbiomed.com
• Phone: 49-6131-554-2860
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Mainz Biomed: $14.00
• High Price Target: $14.00
• Low Price Target: $14.00
• Potential Upside/Downside: +769.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 1.32
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $890 thousand
• Price / Sales: 8.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 4,580,000
• Free Float: N/A
• Market Cap: $7.37 million
• Optionable: Not Optionable
• Beta: 0.25